This retrospective study aims to assess the efficacy of infliximab by intravenous infusion in treating pediatric non-infectious uveitis, including as a second-line anti-tumor necrosis factor (TNF) for patients with insufficient control from adalimumab.
GentileP, RagusaE, BollettaE, et al.Epidemiology of Pediatric Uveitis. Ocul Immunol Inflamm2023;31(10):2050–2059; doi: 10.1080/09273948.2023.2271988
4.
TsiroukiT, DastiridouA, SymeonidisC, et al.A Focus on the Epidemiology of Uveitis. Ocul Immunol Inflamm2018;26(1):2–16; doi: 10.1080/09273948.2016.1196713
RypdalV, GlerupM, SongstadNT, Nordic Study Group of Pediatric Rheumatology. et al.; Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study. Ophthalmology2021;128(4):598–608; doi: 10.1016/j.ophtha.2020.08.024
7.
Angeles-HanST, RingoldS, BeukelmanT, et al.2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis. Arthritis Care Res (Hoboken)2019;71(6):703–716; doi: 10.1002/acr.23871
8.
FosterCS, KothariS, AnesiSD, et al.The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol2016;61(1):1–17; doi: 10.1016/j.survophthal.2015.07.001
9.
ConstantinT, FoeldvariI, AntonJ, et al.Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: The SHARE initiative. Ann Rheum Dis2018;77(8):1107–1117; doi: 10.1136/annrheumdis-2018-213131
10.
ElliottMJ, MainiRN, FeldmannM, et al.Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum1993;36(12):1681–1690; doi: 10.1002/art.1780361206
11.
RamananAV, DickAD, JonesAP, SYCAMORE Study Group. et al.; Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med2017;376(17):1637–1646; doi: 10.1056/nejmoa1614160
12.
EnglandNHS. Clinical Commissioning Policy D12/P/b: Infliximab (Remicade) as Anti-TNF Alpha Treatment Option for Paediatric Patients with Severe Refractory Uveitis. NHS England Clinical Commissioning Policy2015.
13.
BellurS, McHargM, KongwattananonW, et al.Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients with Noninfectious Uveitis. JAMA Ophthalmol2023;141(2):150–156; doi: 10.1001/jamaophthalmol.2022.5584
14.
LeinonenST, AaltoK, KotaniemiKM, et al.Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis Anti-adalimumab antibodies in JIA-uveitis. Clin Exp Rheumatol2017;35(6):1043–1046.
15.
SimoniniG, DruceK, CimazR, et al.Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: A systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken)2014;66(7):1073–1084; doi: 10.1002/acr.22214
16.
JabsDA, NussenblattRB, RosenbaumJT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol2005;140(3):509–516; doi: 10.1016/j.ajo.2005.03.057
17.
MoussaG, BhattH, ReekieI, West Midlands CONCERT. et al.; Using the West Midlands CONCERT to characterise regional incidence of acute-onset post cataract surgery endophthalmitis. Eye (Lond)2021;35(6):1730–1740; doi: 10.1038/s41433-020-01158-6
KrepsEO, EppsSJ, ConsejoA, et al.Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye (Lond)2024;38(5):871–876; doi: 10.1038/s41433-023-02795-3
20.
FoeldvariI, NielsenS, Kümmerle-DeschnerJ, et al.Tumor Necrosis Factor-α Blocker in Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Second-line Agents: Results of a Multinational Survey. J Rheumatol2007;34(5):1146–1150. Available from: http://www.jrheum.org
21.
MonacoC, NanchahalJ, TaylorP, et al.Anti-TNF therapy: Past, present and future. Int Immunol2015;27(1):55–62; doi: 10.1093/intimm/dxu102
22.
TranBN, ChanSL, NgC, et al.Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopy. Protein Sci2017;26(12):2392–2398; doi: 10.1002/pro.3306
23.
GisbertJP, MarínAC, McNichollAG, et al.Systematic review with meta‐analysis: The efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed. Aliment Pharmacol Ther2015;41(7):613–623; doi: 10.1111/apt.13083
24.
TrottaMC, AlfanoR, CuomoG, et al.Comparison of timing to develop anti-drug antibodies to infliximab and adalimumab between adult and pediatric age groups, males and females. J Pediatr Pharmacol Ther2022;27(1):63–71; doi: 10.5863/1551-6776-27.1.63
25.
AndersenNN, JessT. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol2014;20(43):16014–16019; doi: 10.3748/wjg.v20.i43.16014
26.
DeepakP, StobaughDJ, EhrenpreisED. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: Analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis2013;22(3):269–276.
